Deciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation - Slideshow

RTK-, RAS-, and RAF-mutant cancer cells activate autophagy in order to survive stresses or damage due to anti-cancer therapeutic intervention with MAPK and PI3K pathway inhibitors DCC-3116 | POTENTIAL BACKBONE OF COMBINATION THERAPY CENTRAL ROLE FOR AUTOPHAGY IN THE RAS/MAPK AND PI3K PATHWAYS DCC-3116 In Combination with RTK Inhibition DCC-3116 exhibits synergy with osimertinib and afatinib resulting in tumor regression in EGFR-mutant NSCLC in vivo DCC-3116 In Combination with MEK Inhibition DCC-3116 exhibi ...